New center meets growing demand for dialysis in Singapore!
Singapore, 21 November 2018: Fresenius Kidney Care Asia-Pacific, the dialysis treatment and services division of Fresenius Medical Care, has announced the opening of Whampoa Dialysis Center.
Located in the newly transformed Kwong Wai Shiu Hospital (KWSH) Nursing Home and Community Hub, the dialysis center will form part of the largest single-site nursing home in Singapore, enabling easy access to dialysis services for the community's residents. The center will also provide dialysis services for end-stage renal disease (ESRD) patients in the wider Kallang-Whampoa area.
The opening comes at a critical time, as Singapore's population is ageing and rates of obesity, diabetes and high blood pressure are rising - which all play a role in the growing rates of kidney failure.1
Fresenius Medical Care is the world's largest provider of dialysis products and services, and its Kidney Care division focuses on increasing access to treatment for people with kidney failure through its growing network of dialysis centers.
Kidney failure is a worldwide epidemic, of which diabetes is a leading cause.3 In Singapore, the prevalence of diabetes is increasing, and the country now has one of the highest rates of diabetes-induced kidney failure in the world.3,2 Singapore also has an ageing population, accelerating this increase in kidney failure.3
“Currently, almost 6,700 people in Singapore are receiving life-saving dialysis therapy, and every five hours, one more person is diagnosed with kidney failure and will need dialysis,” said Mr Anbu Srinivasan, Managing Director of Fresenius Medical Care Singapore.2 "The increasing number of dialysis patients in Singapore will place even greater pressure on the local healthcare system in the future.3 This new center is a further step towards our goal to help ensure wider access to dialysis care and improve quality of life for patients living with ESRD", he said.
The hospital-based center will offer the option of an advanced form of dialysis known as online hemodiafiltration (HDF). Online HDF allows better removal of waste products from the blood, contributing to improved survival for patients compared with those receiving standard hemodialysis.4,5
As part of the company's holistic approach to patient care, the center will provide additional services including vascular access monitoring, treatment of anaemia, fluid and nutrition monitoring, and regular blood tests.
During dialysis sessions, kidney care nurses will provide patients with health education, focusing on the importance of dialysis-friendly nutrition.
The center was officially opened in a ribbon-cutting ceremony on Saturday 10 November. Officiating at the ceremony were Mr Anbu Srinivasan, Managing Director Fresenius Medical Care Singapore, Dr Akira Wu Yik Tian, Consultant Nephrologist at Wu Nephrology & Medical Clinic and Consultant at Fresenius Kidney Care, and Dr Ow Chee Chung, Chief Executive Officer of Kwong Wai Shiu Hospital.
Speaking at the opening, Medical Director of Fresenius Medical Care, Singapore, Dr Milind Nikam said that Fresenius Kidney Care is one of the largest private providers of dialysis care in the country. “We have a team of 300 healthcare professionals caring for more than 1,300 patients across our network of 28 dialysis centers and home dialysis programs. The new center will provide care for a further 60 patients,” he said.
Furthermore, the new center supports the Singapore Ministry of Health's objective to establish more ‘Active Ageing Hubs’ that provide social and health services to elderly people.
“At Fresenius Kidney Care, we support patients by addressing both the physical and emotional aspects of living with ESRD. We do this by offering personalised care, education and lifestyle support services. This philosophy complements the aims of the Ministry, enabling more Singaporeans to access the care they need so they can ultimately lead more active and fulfilling lives,” added Dr Milind Nikam.
1 National Kidney Foundation (NKF). 'Leading Causes of Kidney Failure'. Available from https://www.nkfs.org/kidney-disease/leading-causes-of-kidney-failure/causes- symptoms-and-treatment/. Accessed 8 November 2018.
2 National Kidney Foundation (NKF). 'Key Statistics on Kidney Diseases'. Available from https://www.nkfs.org/about-nkf/background/key-statistics-on-kidney-diseases/. Accessed 8 November 2018.
3 Health Promotion Board, Singapore. Singapore Renal Registry Annual Report 2016. Available from https://www.nrdo.gov.sg/publications/kidney-failure. Accessed 8 November 2018.
4 Maduell F. et al., J Am Soc Nephrol. (2013); 24(3): 487-497
5 Canaud B. et al; Kidney Int. (2006); 69: 2087-2093
BOUT FRESENIUS MEDICAL CARE
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,872 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 329,085 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialysers. Along with its core business, the company provides related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS).
For more information visit the Company’s website at www.freseniusmedicalcare.com
ABOUT FRESENIUS KIDNEY CARE
Fresenius Kidney Care Asia-Pacific, a division of Fresenius Medical Care Asia-Pacific, provides dialysis services to more than 30,000 people with kidney disease at nearly 400 dialysis centers across the Asia–Pacific region. Fresenius Kidney Care provides care that fits with patients' needs, allowing them to lead more active and fulfilling lives. The care provided addresses both the physical and emotional aspects of living with kidney disease through personalised care, education and lifestyle support services.
For more information visit : www.worldkidneyday.org
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.